Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Roberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, Daniela Cianniello, Claudia Von Arx, Matilde Pensabene, Martina Pagliuca, Carmen Pacilio, Francesca Di Rella, Annarita Verrazzo, Claudia Martinelli, Francesco Nuzzo, Michelino De Laurentiis
Neratinib is a tyrosine kinase receptor inhibitor used in the extended adjuvant therapy of early-stage breast cancer. After adjuvant trastuzumab therapy, neratinib reduces the risk of recurrence and, if taken within 1 year from trastuzumab, significantly improves the invasive disease-free survival of patients with early-stage human epidermal growth factor receptor-2 positive (HER2+) breast cancer with no increased risk of long-term toxicity. Diarrhea, the most common adverse event associated with neratinib use, deters some clinicians from prescribing this drug...
August 2023: Future Oncology
#2
JOURNAL ARTICLE
C Elise Kleyn, Robert McKenzie, Alexandra Meeks, Beatrice Gittens, Lill-Brith von Arx
The prevalence of active atopic dermatitis (AD) in adults in the UK according to disease severity shows variability. This study evaluated disease prevalence and treatment patterns among the adult UK population with AD. Data were obtained from the Clinical Practice Research Datalink (CPRD) database. Adults with active AD were identified by an AD-related prescription or general practitioner visit within the same calendar year. Prevalence was defined as the number of patients with active AD on 1 January of each year as a percentage of the number of adults in the CPRD population on that date...
August 2023: Skin Health Dis
#3
JOURNAL ARTICLE
Michael D Huband, Kelley A Fedler, Helio S Sader, Gregory G Stone, Mariana Castanheira
Ceftibuten/ARX-1796 (avibactam prodrug) is a novel oral antibacterial combination in early clinical development for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. ARX-1796 is the novel avibactam prodrug being combined with ceftibuten for oral dosing that is converted to active avibactam in vivo . A Clinical and Laboratory Standards Institute (CLSI) M23 (2018) tier 2 broth microdilution quality control (QC) study was conducted with ceftibuten-avibactam to establish MIC QC ranges...
July 3, 2023: Journal of Clinical Microbiology
#4
JOURNAL ARTICLE
Dereje A Negatu, Rubén González Del Río, Mónica Cacho-Izquierdo, David Barros-Aguirre, Joël Lelievre, Joaquín Rullas, Patricia Casado, Uday S Ganapathy, Matthew D Zimmerman, Martin Gengenbacher, Véronique Dartois, Thomas Dick
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials...
February 16, 2023: Antimicrobial Agents and Chemotherapy
#5
JOURNAL ARTICLE
Xiaoting Huang, Dayan Xiong, Lang Deng, Wei Liu, Siyuan Tang
OBJECTIVES: The β-cell dedifferentiation is one of the critical mechanisms in diabetic β-cell loss. Long-term activation of N-methyl-D-aspartate (NMDA) receptors plays an essential role in the development of diabetes, but the underlying mechanisms have not been fully elucidated. This study aims to investigate the effect of prolonged activation of NMDA receptors on islet β-cell dedifferentiation. METHODS: Male C57BL/6 mice were randomly divided into a normal control group (control group) and an NMDA group...
2022: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
#6
JOURNAL ARTICLE
Carlos Beltran-Perez, Andrés A A Serrano, Gilberto Solís-Rosas, Anatolio Martínez-Jiménez, Ricardo Orozco-Cruz, Araceli Espinoza-Vázquez, Alan Miralrio
A study of 250 commercial drugs to act as corrosion inhibitors on steel has been developed by applying the quantitative structure-activity relationship (QSAR) paradigm. Hard-soft acid-base (HSAB) descriptors were used to establish a mathematical model to predict the corrosion inhibition efficiency (IE%) of several commercial drugs on steel surfaces. These descriptors were calculated through third-order density-functional tight binding (DFTB) methods. The mathematical modeling was carried out through autoregressive with exogenous inputs (ARX) framework and tested by fivefold cross-validation...
May 3, 2022: International Journal of Molecular Sciences
#7
REVIEW
Antonella Lucia Marretta, Giuseppe Di Lorenzo, Dario Ribera, Lucia Cannella, Claudia von Arx, Alessandra Bracigliano, Ottavia Clemente, Roberto Tafuto, Antonio Pizzolorusso, Salvatore Tafuto
Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors...
September 20, 2021: Pharmaceutics
#8
JOURNAL ARTICLE
Margaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Diana Giannarelli, Michele Aieta, Pasquale Assalone, Laura Attademo, Antonio Avallone, Francesco Bloise, Davide Bosso, Valentina Borzillo, Giuseppe Buono, Giuseppe Calderoni, Francesca Caputo, Giacomo Cartenì, Diletta Cavallero, Alessia Cavo, Fortunato Ciardiello, Raffaele Conca, Vincenza Conteduca, Stefano De Falco, Marco De Felice, Michelino De Laurentiis, Pietro De Placido, Sabino De Placido, Irene De Santo, Alfonso De Stefano, Carminia Maria Della Corte, Rossella Di Franco, Vincenzo Di Lauro, Antonietta Fabbrocini, Piera Federico, Lucia Festino, Pasqualina Giordano, Mario Giuliano, Cesare Gridelli, Antonio Maria Grimaldi, Michela Lia, Antonella Lucia Marretta, Valentina Massa, Alessia Mennitto, Sara Merler, Valeria Merz, Carlo Messina, Marco Messina, Monica Milano, Alessandro Marco Minisini, Vincenzo Montesarchio, Alessandro Morabito, Floriana Morgillo, Brigitta Mucci, Lucia Nappi, Fabiana Napolitano, Immacolata Paciolla, Martina Pagliuca, Giuseppe Palmieri, Sara Parola, Stefano Pepe, Angelica Petrillo, Francovito Piantedosi, Luisa Piccin, Fernanda Picozzi, Erica Pietroluongo, Sandro Pignata, Veronica Prati, Vittorio Riccio, Mario Rosanova, Alice Rossi, Anna Russo, Massimiliano Salati, Giuseppe Santabarbara, Andrea Sbrana, Ester Simeone, Antonia Silvestri, Massimiliano Spada, Paolo Tarantino, Paola Taveggia, Federica Tomei, Tortora Vincenzo, Dario Trapani, Claudia Trojanello, Vito Vanella, Sabrina Vari, Jole Ventriglia, Maria Grazia Vitale, Fabiana Vitiello, Caterina Vivaldi, Claudia von Arx, Francesca Zacchi, Ilaria Zampiva, Andrea Zivi, Bruno Daniele, Paolo Antonio Ascierto
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients...
October 2020: Journal for Immunotherapy of Cancer
#9
JOURNAL ARTICLE
Loredana Poeta, Agnese Padula, Benedetta Attianese, Mariaelena Valentino, Lucia Verrillo, Stefania Filosa, Cheryl Shoubridge, Adriano Barra, Charles E Schwartz, Jesper Christensen, Hans van Bokhoven, Kristian Helin, Maria Brigida Lioi, Patrick Collombat, Jozef Gecz, Lucia Altucci, Elia Di Schiavi, Maria Giuseppina Miano
A disproportional large number of neurodevelopmental disorders (NDDs) is caused by variants in genes encoding transcription factors and chromatin modifiers. However, the functional interactions between the corresponding proteins are only partly known. Here, we show that KDM5C, encoding a H3K4 demethylase, is at the intersection of transcriptional axes under the control of three regulatory proteins ARX, ZNF711 and PHF8. Interestingly, mutations in all four genes (KDM5C, ARX, ZNF711 and PHF8) are associated with X-linked NDDs comprising intellectual disability as a core feature...
November 6, 2019: Human Molecular Genetics
#10
REVIEW
Monica Capozzi, Chiara De Divitiis, Alessandro Ottaiano, Claudia von Arx, Stefania Scala, Fabiana Tatangelo, Paolo Delrio, Salvatore Tafuto
Lenvatinib is an emerging multi-kinase inhibitor with a preferential anti-angiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib...
2019: Cancer Management and Research
#11
JOURNAL ARTICLE
Youngshin Lim, Il-Taeg Cho, Xiuyu Shi, Judith B Grinspan, Ginam Cho, Jeffrey A Golden
Early brain development requires a tight orchestration between neural tube patterning and growth. How pattern formation and brain growth are coordinated is incompletely understood. Previously we showed that aristaless-related homeobox (ARX), a paired-like transcription factor, regulates cortical progenitor pool expansion by repressing an inhibitor of cell cycle progression. Here we show that ARX participates in establishing dorsoventral identity in the mouse forebrain. In Arx mutant mice, ventral genes, including Olig2, are ectopically expressed dorsally...
January 18, 2019: Scientific Reports
#12
JOURNAL ARTICLE
Nathaniel R Glasser, Paul H Oyala, Thomas H Osborne, Joanne M Santini, Dianne K Newman
Arsenate respiration by bacteria was discovered over two decades ago and is catalyzed by diverse organisms using the well-conserved Arr enzyme complex. Until now, the mechanisms underpinning this metabolism have been relatively opaque. Here, we report the structure of an Arr complex (solved by X-ray crystallography to 1.6-Å resolution), which was enabled by an improved Arr expression method in the genetically tractable arsenate respirer Shewanella sp. ANA-3. We also obtained structures bound with the substrate arsenate (1...
September 11, 2018: Proceedings of the National Academy of Sciences of the United States of America
#13
REVIEW
Monica Capozzi, Claudia VON Arx, Chiara DE Divitiis, Alessandro Ottaiano, Fabiana Tatangelo, Giovanni Maria Romano, Salvatore Tafuto
In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs...
October 2016: Anticancer Research
#14
REVIEW
Monica Capozzi, Ieranò Caterina, Chiara De Divitiis, Claudia von Arx, Piera Maiolino, Fabiana Tatangelo, Ernesta Cavalcanti, Elena Di Girolamo, Rosario Vincenzo Iaffaioli, Stefania Scala, Salvatore Tafuto
Neuroendocrine tumors (NET) are rare malignancies, with the most common site of origin being from the gastrointestinal tract, particularly the pancreas, small bowel and appendix. Pancreatic neuroendocrine tumors (PNETs) can be functional, hormone secreting tumors, and can have distinctive symptoms leading to the diagnosis. In contrast nonfunctional tumors, the majority of PNETs, usually present later either incidentally or due to tumor bulk symptoms. Currently Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is the most promising drug for patients with unresectable, metastatic disease, in progressive well-differentiated PNETs and many studies are ongoing to demonstrate its effects on the other neuroendocrine histotipes...
September 2015: International Journal of Surgery
#15
JOURNAL ARTICLE
Rachel J Salisbury, Bing Han, Rachel E Jennings, Andrew A Berry, Adam Stevens, Zainab Mohamed, Sarah A Sugden, Ronald De Krijger, Sarah E Cross, Paul P V Johnson, Melanie Newbould, Karen E Cosgrove, Karen Piper Hanley, Indraneel Banerjee, Mark J Dunne, Neil A Hanley
Diffuse congenital hyperinsulinism in infancy (CHI-D) arises from mutations inactivating the KATP channel; however, the phenotype is difficult to explain from electrophysiology alone. Here we studied wider abnormalities in the β-cell and other pancreatic lineages. Islets were disorganized in CHI-D compared with controls. PAX4 and ARX expression was decreased. A tendency toward increased NKX2.2 expression was consistent with its detection in two-thirds of CHI-D δ-cell nuclei, similar to the fetal pancreas, and implied immature δ-cell function...
September 2015: Diabetes
#16
JOURNAL ARTICLE
Gaia Colasante, Jacqueline C Simonet, Raffaele Calogero, Stefania Crispi, Alessandro Sessa, Ginam Cho, Jeffrey A Golden, Vania Broccoli
Mutations in the Aristaless-related homeobox (ARX) gene are found in a spectrum of epilepsy and X-linked intellectual disability disorders. During development Arx is expressed in pallial ventricular zone (VZ) progenitor cells where the excitatory projection neurons of the cortex are born. Arx(-/Y) mice were shown to have decreased proliferation in the cortical VZ resulting in smaller brains; however, the basis for this reduced proliferation was not established. To determine the role of ARX on cell cycle dynamics in cortical progenitor cells, we generated cerebral cortex-specific Arx mouse mutants (cKO)...
February 2015: Cerebral Cortex
#17
JOURNAL ARTICLE
W Maerki, W Zimmermann, M Faupel, E von Arx
No abstract text is available yet for this article.
January 20, 1984: Journal of Chromatography
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
